Abstract
Imatinib (Glivec or Gleevec) potently inhibits the tyrosine kinase activity of BCR-ABL, a constitutively activated kinase, which causes chronic myelogenous leukemia (CML). Here we report the first almost complete backbone assignment of c-ABL kinase domain in complex with imatinib.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amino Acid Sequence
-
Benzamides
-
Binding Sites
-
Carbon Isotopes / chemistry
-
Fusion Proteins, bcr-abl / antagonists & inhibitors*
-
Imatinib Mesylate
-
Magnetic Resonance Spectroscopy / methods*
-
Molecular Sequence Data
-
Molecular Weight
-
Nitrogen Isotopes / chemistry
-
Piperazines / chemistry*
-
Protein Binding
-
Protein Kinase Inhibitors / chemistry
-
Protons
-
Pyrimidines / chemistry*
Substances
-
Benzamides
-
Carbon Isotopes
-
Nitrogen Isotopes
-
Piperazines
-
Protein Kinase Inhibitors
-
Protons
-
Pyrimidines
-
Imatinib Mesylate
-
Fusion Proteins, bcr-abl